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Abstract
Background: High quality genetic material is an essential pre-requisite when analyzing gene expression using
microarray technology. Peripheral blood mononuclear cells (PBMC) are frequently used for genomic analyses, but
several factors can affect the integrity of nucleic acids prior to their extraction, including the methods of PBMC
collection and isolation. Due to the lack of the relevant data published, we compared the Ficoll-Paque density
gradient centrifugation and BD Vacutainer cell preparation tube (CPT) protocols to determine if either method
offered a distinct advantage in preparation of PBMC-derived immune cell subsets for their use in gene expression
analysis. We evaluated the yield and purity of immune cell subpopulations isolated from PBMC derived by both
methods, the quantity and quality of extracted nucleic acids, and compared gene expression in PBMC and
individual immune cell types from Ficoll and CPT isolation protocols using Affymetrix microarrays.
Results: The mean yield and viability of fresh PBMC acquired by the CPT method (1.16 × 106 cells/ml, 93.3 %) were
compatible to those obtained with Ficoll (1.34 × 106 cells/ml, 97.2 %). No differences in the mean purity, recovery,
and viability of CD19+ (B cells), CD8+ (cytotoxic T cells), CD4+ (helper T cell) and CD14+ (monocytes) positively
selected from CPT- or Ficoll-isolated PBMC were found. Similar quantities of high quality RNA and DNA were
extracted from PBMC and immune cells obtained by both methods. Finally, the PBMC isolation methods tested did
not impact subsequent recovery and purity of individual immune cell subsets and, importantly, their gene
expression profiles.
Conclusions: Our findings demonstrate that the CPT and Ficoll PBMC isolation protocols do not differ in their
ability to purify high quality immune cell subpopulations. Since there was no difference in the gene expression
profiles between immune cells obtained by these two methods, the Ficoll isolation can be substituted by the CPT
protocol without conceding phenotypic changes of immune cells and compromising the gene expression studies.
Given that the CPT protocol is less elaborate, minimizes cells’ handling and processing time, this method offers a
significant operating advantage, especially in large-scale clinical studies aiming at dissecting gene expression in
PBMC and PBMC-derived immune cell subpopulations.
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Background
Gene expression microarray analysis is a powerful method
that can provide a global picture of the transcriptional ac-
tivity in a given biological sample at a particular moment in
time. Most of the traditional molecular biology methods
allow only the investigation of a single or small group of
genes, whereas microarrays can determine expression of
thousands of genes simultaneously. Many studies have
employed microarrays to define gene signatures for diag-
nostic purposes [1–4] and to predict patients’ response to
different treatment regimens [5–9]. Other studies have uti-
lized this technology to recognize molecular mechanisms
underlying disease pathogenesis or its progression [10–14].
As with other RNA-based technologies, the results are to a
large degree influenced by the quality of starting material
and recovered mRNA. Several factors, including sample
collection, storage and transportation, manipulation, and
extraction of nucleic acids and their preservation methods
can affect the integrity of test material [15–18]. Therefore,
careful consideration must be given when designing proto-
cols utilizing the above technologies.
Many gene expression profiling studies have used highly
valuable biopsy tissue from diseased or healthy individuals.
However, such samples may not be readily available and
their procurement might be uncomfortable to patients.
Peripheral blood mononuclear cells (PBMC) have become
a common source of genomic material for microarray
studies, mainly due to the simplicity and relative non-
invasiveness of acquisition [3, 4, 6, 7, 11–14, 19]. The clas-
sical method of PBMC isolation from whole blood applies
Ficoll-Paque density gradient centrifugation [20]. Several
commercially available products have been developed to
simplify PBMC separation. One of the relatively recently
developed approaches is the Vacutainer Cell Preparation
Tube (CPT) from Becton Dickinson (BD). This method
combines a blood collection tube containing sodium cit-
rate anticoagulant and Ficoll-Paque density medium sepa-
rated by a gel barrier. This results in a single tube system
for the collection of whole blood and separation of plasma
and PBMC from erythrocytes and granulocytes. Com-
pared PBMC isolation using Ficoll, the CPT method limits
both technical variability and sample manipulations, and
reduces the processing time. Whereas previous studies
have compared the efficacy, quality and functional capacity
of PBMC obtained by these two methods [21–23], no eval-
uations have been done to assess potential differences in
the recovery and quality of immune cell subsets and the
quality of genetic material derived from these isolated cells.
PBMC are not a homogenous cell population but are
constituted by several immune cell types including, among
others, B cells (~15 %), T cells (~70 %), monocytes (~5 %),
and natural killer (NK) cells (~10 %) [24, 25]. Conse-
quently, the interpretation of microarray results using
total PBMC can be challenging because changes in
proportion of cell subsets or in the expression of a subset-
specific gene can contribute to differences in gene expres-
sion observed in total PBMC. Depending on the type of
disease or treatment applied, the proportion of individual
immune cell subsets in the total PBMC population can
vary considerably [26–28] . Similarly, the method of iso-
lation, delays in processing time, and the technique of
cryopreservation can all affect subset ratios in total
PBMC [18, 23, 29–31]. Another consideration is that
significant fluctuations in subset-specific genes, particu-
larly those which characterize a minority cell subset,
may be overlooked when the entire PBMC population
is examined. This “dilution effect” can be overcome by
the isolation of individual immune cell types prior to
RNA extraction [32], but techniques that require con-
siderable ex vivo handling may significantly impact the
quality of subsequent gene expression analysis [16, 33].
Nevertheless, the isolation of specific immune subsets
is a highly valuable approach that may identify unique
gene expression profiles which are otherwise masked in
the whole PBMC population.
In the current study, we have compared the Ficoll-
Paque density gradient centrifugation and CPT methods
to determine if the more labour-intensive Ficoll tech-
nique can be replaced by CPT to isolate PBMC for
downstream gene expression studies. We evaluated the
recovery and viability of total PBMC purified using both
methods, as well as the quantity and quality of extracted
RNA and DNA. In addition, we used an in-house pro-
cedure to separate pure, multiple immune subsets from
PBMC isolated by Ficoll and CPT approaches to assess
the recovery and purity of each subset, along with the
quantity and quality of extracted nucleic acids. Finally,
we compared gene expression of total PBMC and im-
mune subsets from Ficoll gradient and CPT using
microarray technology.
Methods
Samples and study design
Peripheral blood samples were collected from 6 healthy
adult donors. The samples were collected after approval
by the institutional Health Research Ethic Authority and
signing written informed consent by donors. About
45 ml of blood was obtained from each donor using BD
Vacutainer tubes containing acid-citrate-dextrose anti-
coagulant, solution A (ACD-A; BD) from which PBMC
were isolated by Ficoll-Paque gradient centrifugation
(see below). PBMC were divided into two approximately
equal parts, one for extraction of RNA and DNA, and
the other was cryopreserved for isolation of immune cell
subsets (see below). In parallel, another ~45 ml of blood
from the same donors was collected directly into BD Vacu-
tainer CPT containing 0.1 M sodium citrate and PBMC
were isolated following the manufacture’s instruction (see
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below). The resulting cells were divided into two parts, as
above. Subsequently, B cells, CD4+ and CD8+ T lympho-
cytes, and monocytes were isolated from cryopreserved
Ficoll- and CPT-isolated PBMC. RNA and DNA were
extracted from total PBMC and immune cell subsets ob-
tained after both Ficoll and CPT isolations. Next, gene ex-
pression was analyzed in immune cell subsets and total
PBMC prepared by both methods. The general outline of
the study is presented in Fig. 1.
Isolation of PBMC by Ficoll-Paque density gradient
centrifugation
PBMC were isolated from peripheral blood using Ficoll-
Paque, as previously reported [34, 35]. Briefly, ACD-A-
anticoagulated blood was centrifuged at 800 × g for
30 min and the top layer containing plasma was removed.
The remaining blood was diluted with an equal volume of
phosphate-buffered saline, pH 7.4 (PBS), containing
0.05 M ethylenediaminetetraacetic acid (EDTA; Invitro-
gen). 12.5 ml of diluted blood was layered over 25 ml of
the Ficoll-Paque PLUS (GE Healthcare). Gradients were
centrifuged at 400 × g for 30 min at room temperature in
a swinging-bucket rotor without the brake applied. The
PBMC interface was carefully removed by pipetting and
washed with PBS-EDTA by centrifugation at 250 × g for
10 min. PBMC pellets were suspended in ammonium-
chloride-potassium (ACK) lysing buffer (Invitrogen) and
incubated for 10 min at room temperature with gentle
mixing to lyse contaminating red blood cells (RBC). This
was followed by a wash with PBS-EDTA. Cell number and
viability were determined using a Countess Automated
Cell Counter (Invitrogen). Non-viable cells were identified
by staining with trypan blue and cell viability was calcu-
lated using the total cell count and the count of non-
viable cells. PBMC were cryopreserved in liquid nitrogen
in fetal calf serum (FCS; Invitrogen) containing 10 % di-
methyl sulfoxide (DMSO; Thermo Fisher Scientific) and
stored until required for downstream analyses.
Isolation of PBMC using BD Vacutainer CPT
Immediately following blood collection with Vacutainer
CPT, the tubes were inverted 10 times and centrifuged
Fig. 1 Schematic outline of the study. PBMC from 6 healthy donors were isolated using Ficoll-Paque gradient fractionation or BD Vacutainer CPT
protocol, and cell yield and purity were compared. Subsequently, immune cell subsets were separated by positive selection from PBMC obtained by
both methods, and yields and viabilities of the subsets were determined and compared. RNA and DNA were extracted from total PBMC isolated by
both protocols and from their subsets, and the nucleic acid yield and quality compared. Finally, gene expression analysis of individual immune cell
subsets and total PBMC obtained by Ficoll and CPT isolation methods were performed and the results compared. LN2, liquid nitrogen
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at 1,700 × g for 30 min at room temperature in a
swinging-bucket rotor. After centrifugation, 3 ml of
plasma was removed from the uppermost layer. The
PBMC layer was gently suspended in the remaining
plasma and transferred to 15-ml conical tubes and
washed with PBS by centrifugation at 300 × g for 10 min.
It is of note that an increase in RBC contamination com-
pared to the Ficoll gradient method was visually ob-
served, which was consistent with that reported by the
manufacturer. Therefore, to remain consistent with the
Ficoll protocol, PBMC pellets were re-suspended in
ACK lysing buffer and incubated for 10 min at room
temperature to lyse contaminating RBC and then
washed with PBS by centrifugation. PBMC yield and via-
bility were determined using a Countess Automated Cell
Counter (Invitrogen) and cells were stored in liquid ni-
trogen as described above.
Isolation of immune cell subsets
PBMC isolated by both the Ficoll and CPT methods pre-
destined for cell subset isolations were removed from li-
quid nitrogen storage and thawed on wet ice. Cells were
transferred to 15 ml conical tubes containing RMPI-
1640 medium (Invitrogen) supplemented with 10 %
FCS and 2 mM EDTA and recovered by centrifugation
at 250 x g for 10 min at 4 °C. Then, PBMC were gently
re-suspended in 10 ml RMPI-1640 supplemented with
10 % FCS and 10 mM EDTA, and incubated at 37 °C
for 1 h to allow recovery of the cells prior to subset
separation. PBMC number and viability were deter-
mined as indicated above.
Positive selection of immune cell subsets was performed
by suspending recovered PBMC in 80 μl of autoMACS
running buffer (MACS separation buffer; Miltenyi Biotec)
per 1 x 107 cells and by incubating with 22 μl antibody-
labelled microbeads (Miltenyi Biotec) for 15 min at 4 °C.
PBMC were washed with 10 ml of autoMACS running
buffer by centrifugation at 250 × g for 10 min at 4 °C and
thoroughly re-suspended in 2 ml of the same buffer to en-
sure a single-cell suspension. Separation of microbead-
labelled cells was done using an autoMACS Pro Separator
(Miltenyi Biotec). CD19+ (B cells), CD8+ (cytotoxic T
cells), CD14+ (monocytes), and CD4+ (helper T cell) sub-
sets were isolated from the same PBMC sample in sequen-
tial order using CD19, CD8, CD14, and CD4 microbeads,
respectively. This isolation procedure was developed
through an extensive series of preliminary experiments
and found to be applicable for both freshly isolated and
cryopreserved human PBMC (MacParland et al., manu-
script in preparation). Separation of subsets from PBMC
isolated from an individual donor on Ficoll gradient and
by using CPT was performed simultaneously on two cali-
brated for compatibility autoMACS separators. Cell subset
yield and viability were determined with a Countess
Automated Cell Counter and compared between the two
methods of PBMC isolation. Subset purity was determined
using flow cytometric analysis, as described below. The
isolated cell subsets were re-suspended in RLT Plus buffer
(Qiagen) for subsequent RNA and DNA extractions.
Flow cytometry
Purity of PBMC subsets was determined using flow cyto-
metric analysis immediately following isolation of immune
cell subsets. For each labelling, 2.0 × 105 cells were washed
with autoMACS running buffer as described above and re-
suspended in 100 μl of autoMACS running buffer. Cells
were incubated for 10 min on ice with human Fc receptor
blocking reagent (Miltenyi Biotec), followed by 30 min in-
cubation on ice with fluorochrome-labelled antibodies.
CD19+, CD8+, CD14+, and CD4+ cell subsets were stained
with allophycocyanin (APC)-conjugated anti-human CD19
(HIB19; eBioscience, San Diego, CA), Alexa Fluor 488-
conjugated anti-human CD8 (OKT8; eBioscience), R-
phycoerythrin (PE)-conjugated anti-human CD14 (61D3;
eBioscience), and peridinin chlorophyll protein (PerCP)-
Cy5.5-conjugated anti-human CD4 (RPA-T4; eBioscience),
respectively. Incubations with matched immunoglobulin
isotypes were done in parallel as controls using APC-
conjugated mouse IgG1 (P3; eBioscience), Alexa Fluor
488-conjugated mouse IgG2a (eBM2a; eBioscience),
PE-conjugated mouse IgG1 (P3; eBioscience), or PerCP-
Cy5.5-conjugated mouse IgG1 (P3; eBioscience). After in-
cubation with antibody, cells were washed twice with 2 ml
of autoMACS buffer by centrifugation at 300 × g for
10 min at 4 °C, fixed in 2 % paraformaldehyde (Sigma) in
PBS, washed again, and analyzed with a BD FACSCalibur
bench top flow cytometer. The data were analysed using
FlowJo 7.6 software (Flowjo, LLC).
Extraction, quantitation, and qualitative analysis of RNA
and DNA
RNA and DNA were simultaneously extracted from total
PBMC or individual immune cell subsets, and purified
using the AllPrep DNA/RNA Mini Kit (Qiagen) follow-
ing the manufacturer’s instruction. RNA quantitation
and quality were determined using an Agilent 2100 Bioa-
nalyzer (Agilent and the RNA 6000 Nano Kit (Agilent),
according to the manufacturer’s manuals. RNA quality
was assessed using the RNA integrity number (RIN), a
numerical score of the integrity of RNA, as reported by
others [17, 36, 37]. The yield and purity of DNA were
determined by spectrophotometric measurements of the
ratio of UV absorbance at 260 and 280 nm by a Nano-
drop 2000 (Thermo Fisher Scientific).
Acquisition and analysis of gene expression data
The Affymetrix Human Genome U133 Plus 2.0 array Gen-
eChips (Affymetrix, Inc.) were used for gene expression
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profiling and the evaluation was performed by Expression
Analysis, Inc. The microarray contained more than 54,000
probe sets representing approximately 47,400 transcripts,
allowing the analysis of over 38,500 genes. RNA samples
were converted to amplified cDNA using the NuGEN Ova-
tion RNA Amplification System version 2 (NuGEN) and
subsequently labeled using the NuGEN Encore Biotin
Module for hybridization onto the Affymetrix GeneChips.
First strand cDNA was reverse transcribed from RNA
(50 ng) using a DNA/RNA chimeric primer followed by
second strand synthesis to generate double-stranded cDNA.
Single primer isothermal amplification (SPIA) was then
performed using a DNA/RNA chimeric primer, DNA poly-
merase, and RNase H. To generate labeled cDNA, 3.75 μg
of purified SPIA-amplified cDNA was fragmented and
labeled by enzymatic attachment of a biotin-labeled nucleo-
tide to the 3-hydroxyl end. For hybridization, a
hybridization cocktail was added to the labeled cDNA
target using the Hybridization, Wash and Stain kit (Affyme-
trix, Inc.), applied to the microarrays, and incubated for
18 h at 45 °C. Following hybridization, the microarrays were
washed and stained according to standard Affymetrix pro-
cedures before scanning on an Affymetrix GeneChip Scan-
ner. The data were collected using Affymetrix Expression
Console Software.
Microarray data were analyzed using Partek Genomics
Suite software, version 6.6 (Partek Inc.) and Affymetrix
Expression Console Software. The standard quality met-
rics of Partek and principle component analysis (PCA)
were used for visualization of sample distribution to de-
tect potential outliers [38]. To identify differentially
expressed genes within a given cell type between the
cells derived from PBMC isolated by the CPT and Ficoll
methods, a two-group comparison with permutation
analysis for differential expression, which provides an es-
timate of the false discovery rate (FDR) for each tran-
script comparison [39], was performed by an expert
consultant (Expression Analysis, Inc.). Only transcripts
that had a FDR less than 0.05 were defined as being sig-
nificantly differentially expressed. When no significant
differences were detected, transcripts with a FDR less
than 0.1 were considered. The Affymetrix microarray
data obtained during this study (30 samples) have been
deposited in the NCBI’s Gene Expression Omnibus
(GEO) [40] and are accessible through GEO Series ac-
cession number GSE67321 [http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE67321].
Statistical analysis
Where indicated, the Student’s paired t-test (P < 0.05) ac-
companied by the Shapiro-Wilk test for normality (P <
0.05) were performed in order to compare PBMC yield
and viability, immune cell subset yield and viability, and
RNA and DNA yield and quality between the Ficoll and
CPT PBMC isolation methods.
Results
Equivalent yield and viability of PBMC isolated using
Ficoll or CPT protocols
The number and viability of PBMC from 6 healthy do-
nors was assessed immediately following isolation by ei-
ther the Ficoll or CPT technique and compared between
the two. As described in the Methods, a RBC lysis step
was included after purification of PBMC by both Ficoll
and CPT protocols to minimize the impact of potentially
contaminating RBC- and reticulocyte-derived RNA on
downstream RNA and gene expression analyses. To cor-
rect for variation in the volume of blood used for PBMC
isolation, a relative PBMC yield was calculated by divid-
ing the total number of cells by the milliliters of blood
from which the cells were isolated. The mean number of
PBMC per ml of blood isolated by using the Ficoll method
was 1.16 × 106 cells/ml (SEM= 1.49 × 105, range = 5.71 ×
105 – 1.67 × 106) compared to 1.34 × 106 cells/ml (SEM =
1.19 × 105, range = 9.43 × 105 – 1.71 × 106) for the CPT
technique (Fig. 2a). Thus, there was no significant differ-
ence in the number of PBMC isolated between the two
methods (P = 0.398). The mean number of PBMC ob-
tained per each CPT isolation (9.87 × 106, SD = 3.71 × 106,
range = 4.95 × 106 – 1.80 × 107; n = 29) was comparable to
that reported by the manufacturer (1.27 × 107, SD = 4.64 ×
106, range = 7.02 × 106 – 2.14 × 107; n = 10). Both methods
also resulted in isolation of similarly highly viable PBMC.
The mean viability of Ficoll-isolated PBMC was 97.2 %,
while that obtained by CPT method was 93.3 % (Fig. 2b)
and this was not significantly different (P = 0.057).
High purity and comparable viability of immune cell
subsets derived from Ficoll- and CPT-isolated PBMC
Extensive evaluations performed prior to this study has
resulted in the development of a standardized protocol
allowing for the separation of highly pure B cells
(CD19+), CD8+ T cells (CD8+), CD4+ T cells (CD4+)
and monocytes (CD14+) from a single PBMC sample
using an automated, magnetic bead-based, positive selec-
tion technique (MacParland et al., manuscript in prepar-
ation). Additional preliminary experiments showed that
cryopreserved PBMC are a suitable source for positive
selection of immune cells when compared to freshly
isolated PBMC. The current study showed that the
PBMC recovery from storage in liquid nitrogen was not
significantly different (P = 0.057) when PBMC were iso-
lated using either Ficoll or CPT (Fig. 3a). The mean
percent recovery of PBMC obtained by Ficoll was
77.6 % (SEM = 10.7, range = 56.7–100.0) compared to
57.1 % (SEM = 5.1, range = 40.3–73.6) for CPT-isolated
PBMC. Furthermore, the viability of recovered PBMC
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was excellent and did not significantly differ (P = 0.141)
between Ficoll and CPT isolated cells, where the mean
viabilities were 94.5 % (SEM = 1.7, range = 89.0–99.0 %)
and 95.3 % (SEM = 1.6, range = 89.0–99.0 %) for Ficoll
and CPT, respectively (Fig. 3b). These results were in
agreement with previous reports that demonstrated similar
post-cryopreservation recoveries and viability [18, 21, 22].
Taken together, the above results indicated that cell recov-
ery from cryopreservation was not affected by the PBMC
isolation method and supported our previous findings that
cryopreserved PBMC are appropriate for isolation of
immune cell subsets (MacParland et al., manuscript in
preparation).
Accordingly, CD19+, CD8+, CD14+, and CD4+ cells
were sequentially separated from each PBMC sample
examined and their quantity and viability compared. Pu-
rities of CD19+, CD8+, CD14+, and CD4+ cells were
evaluated by flow cytometry and were found to be
Fig. 2 Yield and viability of PBMC isolated by the Ficoll and CPT protocols. a The mean numbers of PBMC per ml of blood obtained by Ficoll or
CPT isolation procedure from 6 healthy donors. b The mean viability of PBMC freshly isolated from the same 6 healthy donors by either Ficoll
gradient separation or CPT technique. No significant differences (P < 0.05) in PBMC yield or viability between the two isolation protocols were
found. Error bars indicate standard error of the mean
Corkum et al. BMC Immunology  (2015) 16:48 Page 6 of 18
usually 95 % or greater for cells derived from PBMC iso-
lated by either Ficoll or CPT, as shown for cells from
one of the donors in Fig. 4.
Also, no significant differences were found when com-
paring the number or yield of CD19+, CD8+, CD14+,
and CD4+ cells from PBMC separated by Ficoll or CPT
protocol (Fig. 5a). The mean numbers of positively se-
lected B lymphocytes were 1.42 × 106 (SEM = 3.19 × 105)
and 1.32 × 106 (SEM = 3.05 × 105) for Ficoll- and CPT-
derived PBMC, respectively (P = 0.638). The mean num-
ber of CD8+ T cells obtained from Ficoll-isolated PBMC
was 2.01 × 106 (SEM = 3.08 × 105), while that from CPT-
isolated PBMC was 1.74 × 106 (SEM = 1.70 × 105) (P =
0.453). Comparable (P = 0.595) numbers of monocytes
were also acquired from PBMC prepared by both tech-
niques, with a mean yield of 3.87 × 106 (SEM = 6.01 ×
A
B
Fig. 3 Post-cryopreservation recovery and viability of PBMC isolated by the Ficoll and CPT methods. a The mean percent recovery after cryopreservation
of PBMC collected using the Ficoll and CPT protocols. Percent recovery was calculated by dividing the number of PBMC recovered after thawing by the
number of cells that were cryopreserved. b The mean viability of recovered PBMC isolated by the Ficoll and CPT technique. No significant differences
(P< 0.05) in percent recovery or viability between the two protocols were observed. Error bars represent standard error of the mean
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105) and 3.63 × 106 (SEM = 5.28 × 105) cells from Ficoll-
and CPT-derived PBMC, respectively. Lastly, the mean
yield of CD4+ T lymphocytes was 2.48 × 106 (SEM= 4.39 ×
105) for Ficoll-PBMC compared to 1.77 × 106 (SEM=
1.74 × 105) for CPT-PBMC with no significant difference
detected (P = 0.165). These results indicated that the em-
ployment of the CPT protocol for PBMC collection does
not alter the reciprocal proportions between isolated
immune cell subsets or the surface expression of immune
cell-defining surface molecules in comparison to the isola-
tion of PBMC by the Ficoll method.
Similar to yields of individual immune cell subsets, a
comparison of viability between immune cells obtained
from PBMC isolated by Ficoll and those by CPT method
was assessed. These two PBMC isolation protocols did
not result in any significant differences (Fig. 5b). Thus, the
mean viabilities of CD19+, CD8+, CD14+, and CD4+ cells
from Ficoll-PBMC were 93.5, 92.3, 93.5, and 90.7 %
respectively, compared to 92.0, 94.0, 94.0, and 92.2 % for
CPT-PBMC (P = 0.537, P = 0.175, P = 0.864, and P = 0.151,
respectively). This clearly indicated that the CPT method
of PBMC isolation does not adversely affect integrity of
any of the PBMC subsets and that the use of either Ficoll
or CPT for PBMC isolation in combination with the se-
quential immune cell isolation protocol provides viable
cells for downstream evaluations, as the analysis of the
gene expression profiles confirmed (see below).
PBMC isolation method did not influence the quantity or
quality of nucleic acids extracted
Since the yields of viable immune cells from PBMC iso-
lated by Ficoll and CPT were similar, it was expected
that this would also hold true when comparing the
amounts of RNA and DNA extracted from these cells.
As indicated, RNA and DNA were extracted from both
total PBMC and individual immune cell subsets isolated
from these PBMC. To compare yields, the amount of
RNA and DNA was normalized to the number of cells
used for extraction. The mean amount of RNA attained
from total CPT-PBMC was 0.90 pg/cell, which was simi-
lar to 0.86 pg/cell for Ficoll-PBMC (P = 0.871) (Fig. 6a).
The average yields of RNA from B cells derived from
Ficoll- and CPT-PBMC were 0.73 pg/cell and 0.65 pg/
cell, respectively (P = 0.507); CD8+ T lymphocytes,
0.66 pg/cell and 0.50 pg/cell, respectively (P = 0.365);
monocytes, 1.43 pg/cell and 1.28 pg/cell, respectively
(P = 0.187), and CD4+ T lymphocytes, 0.77 pg/cell and
0.57 pg/cell, respectively (P = 0.266) (Fig. 6a). Similar to
RNA yields, there were no significant differences in the
yields of DNA (Fig. 7a). Thus, the average amount of
DNA extracted from Ficoll-PBMC, and CD19+, CD8+,
CD14+ and CD4+ cells derived from these PBMC were
3.76, 5.13, 4.60, 4.01 and 4.42 pg/cell, respectively, com-
pared to 3.74, 5.92, 5.35, 4.03, and 5.71 pg/cell for the
same cells derived by CPT isolation protocol (P = 0.977,
Fig. 4 Purity of immune cell subsets obtained from PBMC isolated by either Ficoll or CPT procedures. CD19+, CD8+, CD14+, and CD4+ cell subsets
were sequentially separated from PBMC isolated by Ficoll and CPT protocols from the same donor and their purity was determined by flow cytometry
using antibodies against surface markers specific for individual immune cell types. Filled histograms were given by appropriate immunoglobulin
isotype controls. Gates for determining positivity were established using isotype controls so that ~99.0 % of events were negative
Corkum et al. BMC Immunology  (2015) 16:48 Page 8 of 18
0.142, 0.227, 0.955, and 0.141, respectively). Overall, the
results indicated that the PBMC isolation method did not
affect the number of separated immune cell subsets or the
amount of nucleic acids extracted.
The integrity of RNA is of paramount importance for
experiments that attempt to measure gene expression in
biological samples when using Affymetrix microarrays.
The RNA integrity is relatively less important when
using RT-PCR and nanostring technology, although the
downside with these technologies is the limitation to
much smaller number of genes which expression can be
analyzed simultaneously. In this study, the quality of
Fig. 5 Yield and viability of immune cell subsets prepared from PBMC isolated by either Ficoll or CPT protocol. a The mean number of CD19+,
CD8+, CD14+, and CD4+ cells positively selected from Ficoll- and CPT-isolated PBMC collected from 6 healthy donors. The horizontal line denotes
the means and each symbol represents an individual cell type isolated from Ficoll-PBMC (filled symbols) or CPT-PBMC (empty symbols) from each
of 6 donors. b The mean viability of the same cell subsets. No significant differences (P < 0.05) in yields and viability of the immune cell subsets
obtained from PBMC isolated by Ficoll and CPT protocols were found. Error bars indicate standard error of the mean
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extracted RNA from each cell sample was determined
using the RNA RIN to compare whether collection of
PBMC by CPT may augment RNA degradation in com-
parison to Ficoll. The average RIN of RNA preparations
from total PBMC was nearly identical between Ficoll
(9.82 ± 0.06) and CPT (9.65 ± 0.15) (P = 0.414), where a
RIN equal to 10 indicates fully intact RNA (Fig. 6b).
Likewise, the use of CPT for PBMC isolation did not
affect the quality of RNA from B cells (Ficoll: 8.13 ±
0.73; CPT: 8.37 ± 0.40; P = 0.781); CD8+ T lymphocytes
(Ficoll: 8.45 ± 0.25; CPT: 8.53 ± 0.16; P = 0.702); monocytes
(Ficoll: 9.12 ± 0.22; CPT: 8.88 ± 0.14; P = 0.355), and
CD4+ T lymphocytes (Ficoll: 8.58 ± 0.39: CPT: 8.22 ±
0.24; P = 0.309), when compared with the respective
subsets derived from PBMC isolated on Ficoll (Fig. 6b).
The quality of DNA was assessed using the ratio of
UV absorbance at 260 and 280 nm and compared be-
tween cell types prepared from Ficoll-PBMC and CPT-
PBMC. The mean 260/280 ratios of DNA from total
PBMC were equivalent between Ficoll (1.81) and CPT
Fig. 6 Yield and quality of RNA recovered from total PBMC and their individual immune cell subsets did not significantly differ between PBMC isolated by
Ficoll and CPT methods. a The mean amount of RNA per cell and (b) the mean RIN of RNA preparations extracted from total PBMC and their individual
immune cell subsets derived from PBMC prepared by Ficoll and CPT methods from 6 health donors. There were no significant differences (P< 0.05) in the
amount of RNA obtained and in the quality of RNA, as measured by RIN, between the two methods of PBMC isolation. Error bars indicate standard error of
the mean. RIN, RNA integrity number
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(1.83) preparations and did not significantly differ (P =
0.249) (Fig. 7b). The same was true for mean DNA 260/
280 ratios for DNA isolated from CD19+ cells (Ficoll:
1.76; CPT: 1.77; P = 0.918), CD8+ cells (Ficoll: 1.81; CPT:
1.82; P = 0.758), CD14+ cells (Ficoll: 1.82; CPT: 1.84; P =
0.216), and CD4+ cells (Ficoll: 1.87; CPT: 1.81; P =
0.186) (Fig. 7b). Taken together, the above findings
clearly demonstrated that the CPT protocol of PBMC
isolation can substitute the Ficoll isolation of PBMC
when immune cell subsets need to be purified without
compromising quantity of the cells, and quantity and in-
tegrity of nucleic acids.
PBMC isolation method did not affect the gene
expression profile of total PBMC and immune cell subsets
Previous reports have demonstrated that experimental
handling and manipulation, including the method of
tissue collection and preparation, can adversely affect
gene expression in primary cells and tissues, which can
interfere with the biological interpretation of results
Fig. 7 Similar quantities of DNA with comparable quality were obtained from PBMC and immune cell subsets following either Ficoll or CPT
protocol of PBMC isolation. a The mean amount of DNA extracted per cell and (b) the mean of the 260/280 ratios, as measure of DNA quality,
were compared between DNA preparations obtained from total PBMC and immune cell subsets prepared from PBMC isolated by Ficoll and CPT
methods from 6 healthy donors. There were no significant differences (P < 0.05) in the amount of DNA recovered and in its quality between the
two methods of PBMC isolation. Error bars indicate standard error of the mean
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[15–18]. To compare gene expression between cell sub-
sets from PBMC prepared by Ficoll and CPT isolation
procedures, gene expression profiles were generated on
the Affymetrix Human Genome U133 Plus 2.0 Array.
We first performed PCA using all genes to visualize the
global distribution of gene expression. PCA is a mathem-
atical technique used to determine the key sources of vari-
ation in a multidimensional dataset by reducing the
dimensionality of the dataset by finding new variables,
termed principle components (PC). Using these principle
components, each sample can be characterized by a few
values which can be plotted, thus allowing a visual assess-
ment of differences and similarities between samples [38].
PCA has been widely used in the analysis and visualization
of microarray data [41, 42]. In the PC#1 vs PC#2 plot
shown in Fig. 8, it is clearly evident that the predominant
variation in gene expression between samples was attrib-
utable to cell type. Samples of the same cell type formed
distinct clusters away from other cell types in the PC#1 vs
PC#2 plot, which accounted for 19.3 % and 12.1 % of the
total variance, respectively (Fig. 8). Given their similar cel-
lular onotology, both T cell subset samples, CD8+ and
CD4+, were grouped together more closely than the other
immune cell types, indicating a close relation in terms of
gene expression. Interestingly, samples processed with
either Ficoll or CPT, within a given cell type, were also
found closely grouped. Further analyses of the signal
scatter plots comparing the intensities of gene expression
between total PBMC and individual immune cell subsets
purified from these PBMC obtained by either Ficoll or
CPT gave similar results as above. The pattern of gene ex-
pression also was very similar between Ficoll and CPT-
derived PBMC and their immune cell subsets obtained
from each donor, with Pearson’s correlation coefficients
greater than 0.96 for all comparisons (Fig. 9). Taken to-
gether, these results showed that in regard to a given cell
type there was little or no difference in gene expression
between the two PBMC isolation methods.
To identify specific genes that were significantly differ-
entially expressed between the Ficoll and CPT isolation
protocols within a given immune cell type, a two-group
comparison with permutation analysis for differential ex-
pression, which estimates the FDR for each comparison,
was performed. Transcripts were considered to be differ-
entially expressed when having a FDR less than 0.05.
When no differentially expressed transcripts were de-
tected at the FDR <0.05 level, the statistical stringency was
reduced to a include transcripts having a FDR less than
0.1. This analysis resulted in no significant differences be-
ing detected in gene expression between Ficoll and CPT
protocols for PBMC (Additional file 1: Table S1) and im-
mune subsets (Additional file 2: Table S2; Additional
file 3: Table S3; Additional file 4: Table S4; Additional
file 5: Table S5). These results implied that there were no
Fig. 8 Principle component analysis of gene expression showing distinct clusters between individual immune cell subsets but not between the same
subsets derived from PBMC isolated by CPT or Ficoll protocols. Principle component analysis (PCA) was performed based on expression of all genes
from the microarray. Individual immune cell types are represented by different colors: CD19+ B cells, blue; CD8+ T cells, green; CD14+ monocytes,
purple; CD4+ T cells, orange; and total PBMC, red. The method used for PBMC isolation is represented by different symbols of differing size: CPT-based
procedure by large circles and Ficoll-based procedure by small circles. PC#1, principle component #1; PC#2, principle component #2
Corkum et al. BMC Immunology  (2015) 16:48 Page 12 of 18
significant alterations in gene expression in PBMC and all
immune cell types when CPT was substituted for Ficoll to
isolate PBMC. We did not attempt to identify gene
signatures that differentiated individual immune cell pop-
ulations because this was not the focus of this study and
this type of analysis has been done by others [43–47].
Fig. 9 Signal scatter plots comparing the intensities of gene expressions on microarray chips within Ficoll and CPT-derived PBMC and their immune
cell subsets for each healthy donor tested. The expression signals of Ficoll-derived cells were plotted against the expression signals of CPT-derived cells
for each cell type and donor. A line of perfect correlation is indicated in all plots. Pearson’s correlation coefficients between each pair of samples are
shown at the bottom right of each plot. The data showed that the pattern of gene expression was very similar between Ficoll and CPT-derived cell
types, as indicated by the high correlation coefficients
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Discussion
The evaluation of the transcriptome of PBMC in ex vivo
or in vitro situations using high throughput technologies,
such as gene expression microarrays, is frequently applied
to advance our general understanding of biological pro-
cesses and specific disease mechanisms in particular. The
availability of the BD Vacutainer CPT method to isolate
human PBMC offers a significant advantage over the
Ficoll method in that it minimizes variations in technical
processing, simplifies isolation procedure, and reduces the
length of elapsed time before RNA isolation. Despite pre-
vious reports emphasizing the effect of different collection
and preparation methods on gene expression in isolated
cells of interest [15–18], the CPT method has not been
comprehensively evaluated in comparison to other blood
cell collection techniques. In the current study, a direct
comparison between the CPT and Ficoll method of PBMC
isolation was done to determine if one method may have a
significant advantage over the other in regard to the im-
mune cell yield, viability, recovery of their individual cell
types, quality of extracted nucleic acids, and gene expres-
sion in both total PBMC and positively-selected immune
cell subsets.
Previous reports which have evaluated the yield of
PBMC using the CPT method in comparison to the
Ficoll technique have been inconsistent in their findings
[21–23]. As in the present study, Ruitenberg et al. ob-
served statistically equivalent numbers of cells isolated
using Ficoll (2.98 × 106 cells/ml) and CPT (2.68 × 106
cells/ml) [21]. Another study also found similar yields by
these two methods at one clinical site (Ficoll, 1.27 × 106
cells/ml; CPT, 1.36 × 106 cells/ml), but at a second site
reported similar, although statistically significantly fewer
PBMC numbers after CPT isolation (1.34 × 106 cells/ml)
compared to Ficoll (1.58 × 106 cells/ml), suggesting that
technical ability of personnel may have an impact on
sample collection and/or cell recovery [22]. In contrast,
Schlenke et al. reported that the CPT method resulted
in significantly higher yields of isolated PBMC compared
to the Ficoll isolation protocol [23]. These differences
are likely due to some variations in technical expertise,
protocols and reagents used in each study. For example,
our CPT procedure incorporated a red blood cell lysing
step followed by additional washes which may have con-
tributed to the slightly lower yields compared to others
[21, 48]. There was a trend, although not statistically sig-
nificant, toward higher cell viability using Ficoll-isolated
PBMC. Despite this minor difference, our findings sup-
ported the above studies in that the variability of cells
isolated using either the CPT or Ficoll method was con-
sistently greater than 90 % [21, 22].
While cell viability and yield are important characteris-
tics, perhaps even more important is determination
whether CPT- and Ficoll-isolated PBMC display
comparable phenotypic profiles and biological functions.
In this regard, it has been documented that T lympho-
cytes derived from CPT-PBMC exhibit similar responses
to antigenic stimulation as PBMC isolated on Ficoll in
interferon-gamma release immunoassays [21, 22, 48].
Furthermore, CPT-PBMC were equally suitable for sero-
logical typing of human leucocyte antigen (HLA) class I
and detection of HLA antibodies using the complement-
mediated microcytotoxicity technique when compared
to Ficoll-PBMC [23]. They were also found suitable for
the quantification of HIV RNA, HIV p24 antigen, and
HIV anti-viral drug levels [49–51]. Taken together, the
studies utilizing total PBMC isolated via CPT protocol
showed that their phenotype and the spectrum of bio-
logical activities investigated so far were highly compatible
with those of PBMC prepared using the Ficoll method.
The focus of this study was to compare the phenotype
of Ficoll- and CPT-isolated PBMC in terms of their
major immune subset makeup and corresponding gene
expression. Earlier studies have demonstrated that varia-
tions in conventional PBMC isolation techniques can
lead to the selective loss of certain cell subtypes [52–54].
For example, Schlenke et al. observed no difference in
granulocyte contamination between CPT and Ficoll iso-
lated PBMC if samples were immediately processed, but
found that after a delay in processing, CPT were better
at preventing granulocyte contamination, at the expense
of decreasing T a B lymphocyte viability in comparison
to Ficoll-PBMC [23]. Given that comparable numbers of
PBMC were isolated by the two methods in our study, it
was not surprising that no significant differences were
observed in the number of highly pure, positively-
selected B cells (CD19+), T cells (CD4+ and CD8+), and
monocytes (CD14+) between CPT- and Ficoll-isolated
PBMC (Fig. 4; Fig. 5a). Furthermore, the viability of im-
mune subset cells derived from PBMC isolated by CPT
and Ficoll protocols was consistently greater than 90 %
(Fig. 5a). Although the absolute numbers of immune
subsets were not determined in the total PBMC popula-
tions, the results presented here indicate that the
proportion of the major immune subsets is not influ-
enced by the PBMC collection method examined.
Comparable yields of RNA were purified from individ-
ual immune cell subsets from Ficoll- and CPT-isolated
PBMC (Fig. 6a), which was expected given the equiva-
lent yield of these cells. The mean amount of RNA
extracted from total CPT-PBMC and Ficoll-PBMC was
0.90 and 0.86 pg/cell, respectively, almost identical to an
earlier study which reported an RNA yield of 0.90 pg/
cell for PBMC [17]. RNA integrity was maintained
throughout the separation of immune subsets from both
CPT- and Ficoll-PBMC, as evidenced by the high RIN
values (Fig. 6b), which also reflected the high viability of
separated subsets (Fig. 5b). In general, the quality of RNA
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was marginally reduced in the isolated immune cell
subsets compared to total PBMC (RIN > 9.5 vs. > 8.0, re-
spectively), likely due to the effect of the cryopreservation
and thawing performed before the subset separation
protocol. However, RNA integrity was still well above the
acceptable cut-off RIN of 5.0 for the reliable gene expres-
sion quantitation, as suggested by earlier studies [17, 55].
Several studies have made use of CPT to isolate PBMC
for the analysis of gene expression by qRT-PCR and
microarray techniques [33, 56–61], but few have directly
compared gene expression of CPT-PBMC with alterna-
tive methods of PBMC isolation. This is of particular im-
portance given that the method of PBMC purification can
adversely affect gene expression, especially when com-
pounded with additional confounding variables [16, 33].
Whole blood RNA stabilization products such as PAX-
gene (Qiagen) and Tempus (Thermo Fisher Scientific)
minimize ex vivo manipulation compared to leukocyte
isolation techniques. However, whole blood contains large
populations of granulocytes, erythrocytes, and platelets
that contribute to gene expression, which can add a con-
siderable amount of noise when the cells of interest are of
lymphoid origin [62] and can significantly alter the gene
expression profile when compared with isolated PBMC
[45]. Ultimately, the use of whole blood RNA stabilization
techniques or PBMC isolation methods will be deter-
mined by the nature of the scientific questions posed by a
particular study, and the decision to employ CPT will fol-
low this initial judgement. Although limited in the sample
size, the current study did not detect any significant differ-
entially expressed genes between PBMC purified by the
Ficoll and CPT method using the Affymetrix HG-U133
Plus 2.0 microarray. In comparison, Baechler et al. used
qRT-PCR to compare expression of commonly tran-
scribed lymphoid cell genes in PBMC isolated using CPT
or Ficoll and observed comparable levels of expression
when samples were immediately processed [33]. Another
study also found very few differences in the gene expres-
sion profiles of CPT- and Ficoll-PBMC measured using
Affymetrix HG-U133A microarrays [61]. Together with
these earlier findings, the results presented in this study
indicate that gene expression in total PBMC remain
unaltered irrespective of the isolation method employed.
One of the greatest sources of variation in PBMC gene
expression among subjects is differences in the propor-
tions of mononuclear cell subpopulations [45, 58]. This
variation, which is known to differ based on age, sex, dis-
ease status, as well as other factors [26–28], adds an add-
itional layer of complexity to the analysis of microarrays
when they are used to compare the gene expression pro-
file of PBMC between different biological situations, and
subtle but specific changes in a minor immune subset
may be overlooked. In addition, if differentially expressed
genes are detected in a mixed cell population, such as
PBMC, it is difficult to identify which cell type is respon-
sible for the change detected and this confounds interpret-
ation of the biological significance of the finding.
Strategies have been developed to ascertain the extent to
which changes in gene expression in a particular immune
cell type can be detected from a total PBMC population
[46, 63–69]. These gene deconvolution methods are able
to discriminate gene expression of particular cell types
within complex tissues and cell mixtures. They are rela-
tively accurate when working with well-defined cell mix-
tures such as blood. However, they are much less reliable
for mixtures with unknown composition and for discrim-
inating between closely related cell phenotypes. Further-
more, deconvolution methods are limited in that they rely
on the specificity of reference gene profiles, which may
differ in cells and/or tissues in different disease states.
Thus, the isolation of specific cell subsets prior to analysis
of gene expression offers a distinct advantage by providing
insight into immune cell subset-specific changes. For this
reason, we separated B lymphocytes, CD8+ and CD4+ T
lymphocytes, and monocytes from both Ficoll- and CPT-
isolated PBMC to precisely determine whether the PBMC
isolation method had a preferential effect on the immune
cell subsets isolation and their gene expression signature
which may have been masked by the analysis of total
PBMC. The results revealed that there were no significant
differences in gene expression in any of the immune cell
subsets separated from Ficoll- and CPT-isolated PBMC.
Although the current analysis of gene expression did not
include RNA-seq data, it provides a basis of comparison
for future evaluations that may utilize this method. Over-
all, our findings document that either method evaluated
can be substituted for the collection of PBMC without ad-
versely affecting subsequent immune cell subset separ-
ation and the gene expression by the resulting subsets.
Conclusions
The present study demonstrates that the Ficoll isolation
of PBMC can be substituted by the BD Vacutainer CPT
protocol without yielding phenotypic changes in PBMC-
derived immune cell subsets and without compromising
the quality of the subsequent gene expression studies.
Given that the CPT protocol is less elaborate, minimizes
the cells’ handling and processing time, the current
findings indicate that this method offers a significant op-
erating advantage, especially in large-scale clinical stud-
ies aiming at dissecting gene expressions in total PBMC
and their immune cell subset populations.
Availability of supporting data
The microarray data files supporting the results presented
in this article are available in the NCBI’s Gene Expression
Omnibus and are accessible through GEO Series accession
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number GSE67321 [http://www.ncbi.nlm.nih.gov/geo/
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The data sets supporting the results of this article are
included within the article and its additional files.
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